Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
Phase 2
Completed
- Conditions
- Dysmenorrhea
- Interventions
- Drug: Placebo matching 7.5 mg meloxicamDrug: Placebo matching 500 mg mefenamic acidDrug: Placebo matching 15 mg meloxicam
- Registration Number
- NCT02183025
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 337
Inclusion Criteria
- Female patients between 18 to 40 years
- Patients experiencing primary (functional) dysmenorrhea during the last 3 consecutive menstrual periods. Diagnosis will be based on symptoms and clinical signs: abdominopelvic pain, may radiate to the back and along the thighs; systemic symptoms including nausea, vomit, diarrhoea, headache, fatigue, nervousness, dizziness; the symptomatology should be usually some hours to one day before commencement of visible vaginal bleeding
- Evaluation of lumbar and/or abdominopelvic pain due to dysmenorrhea > 35 mm through a 100 mm visual analogue scale (VAS)
- Outpatients
- Patients granting their written informed consent
- Therapy with a NSAID (nonsteroidal antiinflammatory drug) is required or recommended
Exclusion Criteria
- Known or suspected hypersensitivity to trial drugs or their excipients, analgesics, antipyretics or NASIDs
- Analgesic concomitant treatment (between each cycle paracetamol administration will be allowed)
- To initiate hormonal contraception or intrauterine devices after inclusion to this trial or during the last 3 months
- Abdominal surgery or pelvic procedure scheduled during the study
- Patients with organic dysmenorrhea (endometriosis, salpingitis, adnexitis, uterine retroversion, tubal cysts, ovarian cysts, pathological vaginal secretion, painful pelvic exploration, etc.)
- Patients with neoplastic disorders
- History of recent abdominal or pelvic trauma requiring surgery
- Peptic ulcer within the past 6 months
- Pregnancy or breast feeding
- Asthma, nasal polyps, angioneurotic edema or rash following aspirin or NSAIDs administration
- Concomitant treatment with anti-coagulants, including heparin and aspirin, lithium or methotrexate
- Concomitant administration of other NSAIDs (including aspirin > 150 mg daily) or analgesics
- Confinement to bed rest
- Administration of any NSAID during two days (three for oxicams) before the first administration of the trial drug
- Present treatment or treatment within the last two months with corticosteroids
- Impaired renal function (serum urea > 125 % of the upper limit of normal range; serum creatinine > 150 % of the upper limit of normal range)
- Sever liver injury (alanine amino transferase ALAT > 2 x the upper normal range limit or aspartate amino transferase ASAT > 2 x the upper normal range limit)
- Hematological disorder (platelet count < 100,000/mm**3, leucocyte count < 3,000/mm**3)
- Participation in another clinical trial during this study or the previous month
- Previous participation in this trial
- Patient unable to comply with protocol
- Bleeding disorders
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Meloxicam 15 mg Placebo matching 500 mg mefenamic acid - Mefenamic acid 1500 mg Mefenamic acid 500 mg 500 mg three times daily Mefenamic acid 1500 mg Placebo matching 7.5 mg meloxicam 500 mg three times daily Mefenamic acid 1500 mg Placebo matching 15 mg meloxicam 500 mg three times daily Meloxicam 15 mg Placebo matching 7.5 mg meloxicam - Meloxicam 7.5 mg Placebo matching 15 mg meloxicam - Meloxicam 7.5 mg Placebo matching 500 mg mefenamic acid - Meloxicam 7.5 mg Meloxicam 7.5 mg - Meloxicam 15 mg Meloxicam 15 mg -
- Primary Outcome Measures
Name Time Method Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS) Baseline and day 3-5 of each treatment cycle
- Secondary Outcome Measures
Name Time Method Final global assessment of efficacy by patient on a 4-point scale day 3-5 of the second treatment cycle Final global assessment of efficacy by investigator on a 4-point scale day 3-5 of the second treatment cycle Final global assessment of tolerability by patient on a 4-point scale day 3-5 of the second treatment cycle Final global assessment of tolerability by investigator on a 4-point scale day 3-5 of the second treatment cycle Number of Participants with Adverse Events (AE) Up to 4 weeks after last treatment cycle Incidence of significant laboratory events Up to 4 weeks after last treatment cycle Number of perforations, ulcerations and/or bleedings (PUB) of the upper gastro-intestinal tract Up to 4 weeks after last treatment cycle Number of gastro-intestinal adverse events (GI-AEs) Up to 4 weeks after last treatment cycle Duration of hospitalization stay due to GI-AEs Up to 4 weeks after last treatment cycle Number of additional visits at physician due to GI-AEs Up to 4 weeks after last treatment cycle Duration of hospitalization due to drug related AEs Up to 4 weeks after last treatment cycle Number of withdrawals due to AEs Up to 4 weeks after last treatment cycle Change in severity of symptomatology associated with dysmenorrhea Baseline and day 3-5 of each treatment cycle Intensity of AEs on a 3-point scale Up to 4 weeks after last treatment cycle Evaluation of labor and/or daily life disability associated with dysmenorrhea on a VAS Baseline and day 3-5 of each treatment cycle